JAZZ - Jazz Pharma Q4 Xyrem sales up 20%; shares up 10% after hours February, 26 2019 04:38 PM Jazz Pharmaceuticals plc Jazz Pharmaceuticals (NASDAQ:JAZZ) Q4 results (): Revenues: 476.5 (+9.2%). More news on: Jazz Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...